Stromal Vascular Fraction Cell Therapy for a Stroke Patient-Cure without Side Effects

Jaroslav Michalek, Alena Vrablikova, Karl Georg Heinrich, Zuzana Dudasova, Jaroslav Michalek, Alena Vrablikova, Karl Georg Heinrich, Zuzana Dudasova

Abstract

A 48-year-old male, who suffered from a stroke resulting in cerebellum damage and occlusion of the left vertebral artery, underwent stromal vascular fraction therapy. The clinical status of the patient was monitored by a modified Stroke Specific Quality of Life Scale before therapy and at 3, 9, 12, 18, 24, and 32 months after therapy. Three months after therapy, the patient felt a reduction in pain, vertigo, and fatigue. After 9 months, he was able to walk safely on his own. After 24 months, he was able to ride a bicycle. After 32 months, he felt completely healthy without any limitations or handicaps. Therefore, intravenous application of stromal vascular fraction cells represents a promising strategy for the treatment of patients after a stroke.

Keywords: cell therapy; stroke; stromal vascular fraction.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
A total score analyzed by modified Stroke Specific Quality of Life Scale. The score was evaluated in the range from 1 to 100, where 100 reflect the patient’s complete health.

References

    1. Bhasin A., Kumaran S.S., Bhatia R., Mohanty S., Srivastava M.V.P. Safety and Feasibility of Autologous Mesenchymal Stem Cell Transplantation in Chronic Stroke in Indian patients. A four-year follow up. J. Stem. Cells Regen. Med. 2017;13:14–19.
    1. Strioga M., Viswanathan S., Darinskas A., Slaby O., Michalek J. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21:2724–2752. doi: 10.1089/scd.2011.0722.
    1. Michalek J., Moster R., Lukac L., Proefrock K., Petrasovic M., Rybar J., Chaloupka A., Darinskas A., Michalek J., Kristek J., et al. Stromal vascular fraction cells of adipose and connective tissue in patients with osteoarthritis: A case control prospective multi-centric non-randomized study. Glob. Surg. 2017;3:1–9. doi: 10.15761/GOS.1000163.
    1. Williams L.S., Weinberger M., Harris L.E., Clark D.O., Biller J. Development of a stroke-specific quality of life scale. Stroke. 1999;30:1362–1369. doi: 10.1161/01.STR.30.7.1362.
    1. Raposio E., Caruana G., Bonomini S., Libondi G. A novel and effective strategy for the isolation of adipose-derived stem cells: Minimally manipulated adipose-derived stem cells for more rapid and safe stem cell therapy. Plast Reconstr. Surg. 2014;133:1406–1409.
    1. Michalek J., Vrablikova A., Darinskas A., Lukac L., Prucha J., Skopalik J., Travnik J., Cibulka M., Dudasova Z. Stromal vascular fraction cell therapy for osteoarthritis in elderly: Multicenter case-control study. J. Clin. Orthop. Trauma. 2019;10:76–80. doi: 10.1016/j.jcot.2018.11.010.
    1. Fernández O., Izquierdo G., Fernández V., Leyva L., Reyes V., Guerrero M., León A., Arnaiz C., Navarro G., Páramo M.D., et al. Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE. 2018;2018 13:e01958917. doi: 10.1371/journal.pone.0195891.
    1. Qayyum A.A., Mathiasen A.B., Mygind N.D., Kühl J.T., Jørgensen E., Helqvist S., Elberg J.J., Kofoed K.F., Vejlstrup N.G., Fischer-Nielsen A., et al. Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study. Stem Cells Int. 2017;2017:5237063. doi: 10.1155/2017/5237063.
    1. Silva J.D., Lopes-Pacheco M., Paz A.H.R., Cruz F.F., Melo E.B., de Oliveira M.V., Xisto D.G., Capelozzi V.L., Morales M.M., Pelosi P., et al. Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Lung Tissue Differentially Mitigate Lung and Distal Organ Damage in Experimental Acute Respiratory Distress Syndrome. Crit. Care Med. 2018;46:e132–e140. doi: 10.1097/CCM.0000000000002833.
    1. Philandrianos C., Serrero M., Grimaud F., Magalon J., Visée C., Velier M., Francois P., Orsoni P., Magalon G., Grimaud J.C., et al. First clinical case report of local microinjection of autologous fat and adipose-derived stromal vascular fraction for perianal fistula in Crohn’s disease. Stem Cell Res. Ther. 2018;9:4. doi: 10.1186/s13287-017-0736-6.
    1. Cheng Y.Y., Hsieh W.L., Kao Ch.L., Chan R.C. Principles of rehabilitation for common chronic neurologic diseases in the elderly. J. Clin. Geront. Geriatr. 2012;3:5–13. doi: 10.1016/j.jcgg.2011.11.003.
    1. Ouyang Q., Li F., Xie Y., Han J., Zhang Z., Feng Z., Su D., Zou X., Cai Y., Zou Y., et al. Meta-analysis of the safety and efficacy of stem cell therapies for ischemic stroke in preclinical and clinical studies. Stem Cells Dev. 2019 doi: 10.1089/scd.2018.0218.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj